Document is current
Any future updates will be listed below
-
Authors
Cui, Chang
Chakraborty, Kasturi http://orcid.org/0000-0002-0635-9028
Tang, Xu Anna
Schoenfelt, Kelly Q.
Hoffman, Alexandria
Blank, Ariane
McBeth, Blake
Pulliam, Natalie
Reardon, Catherine A.
Kulkarni, Swati A. http://orcid.org/0000-0002-4213-0933
Vaisar, Tomas http://orcid.org/0000-0002-7406-6606
Ballabio, Andrea http://orcid.org/0000-0003-1381-4604
Krishnan, Yamuna http://orcid.org/0000-0001-5282-8852
Becker, Lev
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102960)
- License Information
-
More Information
Article History
Received: 7 May 2020
Accepted: 31 August 2021
First Online: 11 November 2021
Competing interests
: L.B., Y.K., C.C. and K.C. are inventors on a provisional patent (related to DNA-based therapeutics delivery) filed by the University of Chicago. L.B. and Y.K. are co-founders of MacroLogic, a startup biotechnology company focused on developing DNA-conjugated therapeutics. A. Ballabio is a co-founder of CASMA Therapeutics and is an Advisory Board member of Next Generation Diagnostics and of Avilar Therapeutics. X.A.T., K.Q.S., A.H., A. Blank, B.M., N.P., C.A.R., S.A.K. and T.V. declare no competing interests.
